P124 - Molecular determinants of the inherently slow entry of NKTR-181 into the brain
Aleksandrs Odinecs(Nektar Therapeutics (United States)), Stephen K. Doberstein(Xencor (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Michael A. Eldon(Nektar Therapeutics (United States)), Laurie A. VanderVeen(Gilead Sciences (United States)), Myong Lee(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Werner Rubas(University of California, San Francisco)
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403